GPC Shifts Satraplatin Focus From First-Line To Second; Study Cleared In SPA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The German biotech firm GPC will proceed with a Phase III trial of its oral prostate cancer therapy satraplatin as a second-line treatment following FDA’s clearance of a special protocol assessment.
You may also be interested in...
Special Protocol Assessment Requests Up 10%-15% Over FY2002
Sponsor requests for special protocol assessments continue to rise with a 10% to 15% increase so far in 2003, according to FDA.
Cellegy Cellegesic SPA Clears FDA; NDA Resubmission Planned For Q3 2004
Cellegy’s Special Protocol Assessment agreement with FDA for its anal fissure therapy Cellegesic allows the firm to use pain at three weeks as the primary endpoint for a confirmatory trial.
Special Protocol Assessment Requests Up 10%-15% Over FY2002
Sponsor requests for special protocol assessments continue to rise with a 10% to 15% increase so far in 2003, according to FDA.